|
|
 |
|
Industry
Reports |
|
 |
|
|
HighTech Business Decisions currently has the following published
reports available: |
|
Biopharmaceutical
Contract Manufacturing 2011:
New Participants, Expanded Services and Emerging Markets
This 900-page report provides the latest information about the supply and demand for the outsource production of large-molecule API. This report analyzes the biotechnology industry's biomanufacturing strategies, budgets, contractor relationships and new projects. This report also provides detailed analyses of contractor capacity, current and projected utilization rates, and the adoption of disruptive manufacturing technologies. The data and the analysis in this report are based on 70 in-depth interviews conducted by Ph.D.-level analysts with both executives at biopharmaceutical and contractor companies worldwide. The analyses of their perspectives and insights allow readers to gain an understanding of the market and its future direction. This report includes 235 summary data tables and charts, and is the most comprehensive and current industry report on biopharmaceutical contract manufacturing. Published October 2011
>>Table of Contents >>
Order Form |
| |
|
|
|
2011 Directory of Biopharmaceutical
Contract Manufacturers
The 2011 directory provides
a thorough listing of 77 contractors worldwide, including
service offerings, equipment, capacity, cGMP status, and other
important details.
>>Table of Contents >>
Order Form |
| |
|
| |
Biopharmaceutical
Contract Manufacturing:
Best Practices Pricing Study 2011
This 300-page report documents pricing practices, policies, agreements, and strategies for both pharmaceutical and biotechnology companies and contract manufacturers. Learn about industry prices paid to contractors for mammalian cell culture and microbial fermentation production. This report provides batch, time-in-facility, and gram prices. In this report, contract manufacturing prices are analyzed by technology and tank sizes. This report includes both prices paid by users and prices charged by CMOs for contract services. In addition, this report provides extensive information from industry executives on difficult-to-negotiate issues such as liability for failed batches, down payments, cancellation fees, technology transfer fees, process development fees, and more. Published January 2011.
>>Table of Contents >>
Order Form |
| |
|
|
Biopharmaceutical Fill-and-Finish: Best Practices Study 2010
This 515-page report, the comprehensive 2010 industry study, provides the latest information on biomanufacturing fill-and-finish strategies, manufacturing technologies, markets, outsourcing, capacity and demand, contractor relationships, pricing policies and practices, prices paid and charged, and future trends in fill-and-finish contract manufacturing industry including growth opportunities and challenges. The data and the analysis in this report are based on 41 in-depth interviews conducted with biomanufacturing directors at pharmaceutical and biotechnology companies and fill-and-finish contractor companies worldwide. The analysis of these perspectives and insights allow readers to make the most successful strategic decisions. This report includes over 180 summary data tables and charts, and is the most comprehensive and current industry report on biopharmaceutical fill-and-finish contract manufacturing
Published September 2010.
>>Table of Contents >>
Order Form |
| |
|
|
Directory of Biopharmaceutical Fill-and-Finish Contract Manufacturers
This 2010 directory provides a thorough listing of 34 biopharmaceutical fill-and-finish contractors worldwide, including information on type of services offered, equipment capacity, cGMP certification by service category and more.
Published September 2010.
>>Table of Contents >>
Order Form |
| |
|
|
High Throughput
Screening 2010: Effective Strategies, Innovative Technologies,
and Use of Better Assays
This 1050-page
report, with over 300 charts and tables, documents current
HTS practices for drug discovery and the evolving role of
the HTS laboratory in biotech and pharmaceutical companies,
academic centers, and institutes worldwide. This study provides
an in-depth analysis of the current levels of success as
regards to discovering new drugs using HTS, evolving strategies
to increase this success, current and expected use of cell-based
assays and high content screening, detection technologies,
equipment used, targets and target classes growing in importance,
the number of compounds screened, throughput, microplates,
budgets and expenditures by product category, outsourcing
trend, market size and expected growth, unmet needs in HTS,
and the challenges and opportunities in HTS for both users
and their suppliers.
Published February 2010.
>>Table of Contents >>
Order Form |
| |
|
|
|
The History of High Throughput Screening for Drug Discovery: 1998-2005
HighTech Business
Decisions (HTBD) has conducted six market research studies
and published six comprehensive industry reports on high
throughput screening (HTS) since 1998. This report is specifically
designed to understand the changes that have occurred in
HTS since 1998, how accurate HTS directors have been in
forecasting and predicting their use of technology and future
needs, how HTS practices have evolved, and the success of
HTS as a drug discovery tool. Topics include the number
of disease targets screened, target types, assay types,
detection modes, microplate formats, outsourcing, and other
issues impacting HTS operations and success. The complete
analysis, based on both user and supplier primary research,
includes market size and growth, major players, user strategies
and requirements, documentation of success in drug discovery,
trends and technologies, and respondents’ perceptions
regarding the future of HTS.
>>Table of Contents >>
Order Form |
|
|
|
|
|
|
|
|
 |
|
|
|
|
